Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Daily vaping in the United States has surged by 230% between 2013–14 and 2022–23. Additionally nearly half of young adults who vaped daily used high-nicotine e-cigarettes, according to two studies published in the journal Tobacco Control.

The findings have sparked concerns about the increase in nicotine dependence among young people. The studies analysed data from the US Population Assessment of Tobacco and Health (PATH) Study, which tracks tobacco and nicotine use across the country.

Daily Vaping Increased By 230%

The first study examined the patterns of vaping for a decade, from 2013–14 to 2022–23. Researchers found that the total number of vaping days across the population increased by 183%, while vaping in the past 30 days rose by 45%. Daily vaping increased by 230% over the same period.

Vaping days among people younger than 21 who had vaped in the previous 30 days increased by 337%. Among those aged 12–17, the increase was 278%. By 2022–23, people under the legal age of 21 accounted for 16% of all vaping days.

The researchers noted that the sharpest increases in vaping frequency occurred after 2016–18, coinciding with the rise of JUUL and nicotine salt e-liquids, which make nicotine easier to inhale.

“While vaping days increased across all age groups, pronounced increases between 2013–14 and 2022–23 were observed among youth and younger adults, likely influenced by industry marketing that has predominantly targeted young people, as well as increases in the size of the youth population,” the researchers wrote.

They also warned about dual use, in which people smoke cigarettes and vape without fully switching away from smoking, as well as the possibility of ex-smokers returning to nicotine use.

Also read: Selena Gomez Says Vaping Changed Her Voice: How E-Cigarettes Affect Vocal Cords

Nearly Half Of Young Adult Daily Vapers Used High-Nicotine Products

The second study published in the same journal examined use of nicotine e-cigarettes between 2017 and 2022. It found that among daily vapers aged 18–24, the number of people using e-cigarettes containing at least 4% nicotine jumped dramatically from 3.1% in 2017 to 49.2% in 2022.

By comparison, 32.8% of daily vapers aged 25–34 used products with at least 4% nicotine in 2022. The figure was 17.6% among those aged 35–54 and 4.5% among adults aged 55 and older. To sum up, young adults who vaped were 12 times more likely than those aged 55 and older to use high-nicotine products.

The study also linked higher nicotine concentrations with greater chance of dependence. People who used high-nicotine e-cigarettes in 2019 had 31% lower odds of being abstinent from vaping four years later.

“The Food and Drug Administration's (FDA) authorization of these products was based in part on the expectation that the benefits to adults who smoke would outweigh the risks of creating new nicotine dependence among young people. Our findings suggest that this balance needs to be reassessed,” the researchers said.

Senior author John Pierce added, “Previous research has questioned the effectiveness of e-cigarettes in helping smokers quit. In this study, we have documented that high-nicotine products have created a new generation of people who are dependent on nicotine.”

Also read: 5.4 Million Over-16s Now Vape in Britain: Why E-Cigarettes May Not Be Safer

5.4 Million Vape Users In The UK Are 16 Years Old And Above

In Great Britain, around 5.4 million people aged 16 years and over (9.9%) used an e-cigarette daily or occasionally in 2025, according to the ONS Opinions and Lifestyle Survey. For the second consecutive year, e-cigarette use was higher than cigarette smoking. In 2025, there were around:

• 5.4 million current e-cigarette users
• 4.8 million current smokers

The proportion of adults using e-cigarettes has also increased over the longer term, rising from 6.4% in 2020 to 9.9% in 2025.

“Inhaling these substances directly into the lungs introduces not just nicotine, but also numerous potentially carcinogenic and lung-damaging compounds. This is not harm reduction—it’s harm diversification.”, said Dr. Arun Chowdary Kotaru, Head and Senior Consultant of Pulmonology & Sleep Medicine.

He added, "The teenage brain is still developing until around the age of 25. Nicotine interferes with areas responsible for learning, impulse control, and mood regulation. Early exposure can also set the stage for a lifelong struggle with addiction, increasing vulnerability to other substance abuse later in life."

Propranolol is a beta-blocker that is used to address certain heart conditions and physical symptoms of anxiety. It has been gaining attention on social media for calming nerves before stressful life events like job interviews, presentations and other similar situations.

However, experts warn that its surging popularity may make it difficult to pay attention to the limited evidence supporting its use for anxiety.

The medication works by blocking the effects of adrenaline on beta receptors, slowing the heart rate and reducing physical symptoms like trembling, sweating and palpitations. It does not directly treat the emotional symptoms of anxiety.

Propranolol Has Becoming Popular As A 'Quick Fix'

In England, the NHS dispensed around 8.4 million propranolol prescription items in the 12 months leading up to June 2026, a 4.7% increase from the previous year. These figures cover all uses of the drug, not just anxiety.

Significant increases in prescriptions among younger women and teenage girls over a decade was also seen. Social media has helped promote propranolol as a quick fix for nerves, but its popularity does not reflect the strength of its clinical evidence.

Also read: Seasonal Depression & Anhedonia: How Winter Can Affect Pleasure And Motivation

What Does The Evidence Say?

Dr Daniel Gordon, private GP and managing director at DGA Health told Daily Mail that propranolol may help people whose anxiety mainly causes physical symptoms.

"In my experience, the people who find propranolol helpful are usually those whose anxiety shows up mostly in the body, with palpitations, shaking and a pounding chest," Dr Gordon said.

He also said that addressing those symptoms can treat physical symptoms, helping people feel more in control. But feeling calmer in the body is not the same as treating anxiety, and for many people talking therapies, and sometimes other medicines, prove to be helpful.

Additionally, the evidence available on Propranolol is insufficient contrary to its online popularity. A systematic review of eight small randomised trials, covering around 200 people, concluded that the evidence was insufficient to support routine use of propranolol in any anxiety disorder.

Some people do report relief of physical symptoms, but propranolol us not recommended for anxiety as there are no modern, reliable clinical trials.

Dr Gordon added, "This is exactly why proper assessment matters. Propranolol should generally not be used by people with asthma, certain heart rhythm problems such as heart block, a very slow heart rate or low blood pressure, and it can mask the warning signs of low blood sugar in people with diabetes."

Also read: The Silent Struggle Of Raising A Child With Mental Health Challenges: How Parents Can Cope With Stigma

Risks Of Taking Propranolol Without Prescription

Common side effects of propranolol include dizziness, tiredness, cold hands and feet, and sleep disturbances. Because propranolol can decrease heart rate and blood pressure, it may be unsuitable for people with low blood pressure. It can also be risky for people with asthma and heart conditions.

Buying prescription medication online is not inherently unsafe, but a brief questionnaire does not necessarily mean that a person's medical history and individual risks have been adequately assessed.

Gordon stressed that a medical doctor needs to review a patient's medical history before prescribing the drug as it can interact with other medications and may be unsuitable for some patients.

Alternatives For Managing Anxiety

Propranolol may help some people manage physical symptoms in some situations, but it is not a substitute for treating clinical anxiety.

Psychological therapies, including cognitive behavioural therapy (CBT), can help people manage anxious thoughts. Medication may also be appropriate depending on the person's symptoms.

People whose anxiety affects their work, relationships or daily activities should speak to a healthcare professional rather than taking propranolol.

Police in Guinea-Bissau raided the Bandim Health Project on Monday, October 19, and seized a batch of hepatitis B vaccines intended for a controversial trial involving 14,000 newborns, according to an official statement.

The project’s Danish researchers, Peter Aaby and Christine Stabell Benn, are at the center of the dispute. The study received $1.6 million from the US Centers for Disease Control and Prevention (CDC), matched by the Pershing Square Foundation and the Bluebell Foundation, bringing total funding to $3.2 million. US Health and Human Services Secretary Robert F. Kennedy Jr. has praised the researchers’ work.

The police search took place on Monday, involving “investigative procedures aimed at clarifying the circumstances related to the said batch of vaccines”, according to the social media post, which was translated from Portuguese. The announcement noted that seizing the immunizations did not point to “irregularities in the quality, safety, or effectiveness of the vaccines”, The Guardian reported.

Why Is the Hepatitis B Vaccine Trial Controversial?

The proposed trial would randomly divide 14,000 newborns into two groups: one would receive the hepatitis B vaccine at birth, while the other would receive it six weeks later.

The WHO recommends hepatitis B vaccination within 24 hours of birth to prevent mother-to-child transmission.

Why Is Delaying Vaccination a Concern?

Also read: Hepatitis B Infections Could Rise 83% If US Changes Newborn Vaccine Policy: Study

Hepatitis B is highly endemic in Guinea-Bissau, affecting more than 12% of adults. Infants infected at birth have about a 90% chance of developing chronic infection, which can lead to cirrhosis, liver failure and liver cancer.

Stig Børsen Hansen, a member of the University of Southern Denmark’s ethics committee, resigned after the committee narrowly approved the updated protocol. He warned that the trial would expose some newborns to potentially serious infections by delaying vaccination.

What Is the Study Investigating?

Rather than testing the vaccine’s established efficacy, the study aims to investigate the proposed “non-specific effects” of vaccines — potential health effects beyond protection against targeted infections.

Critics argue that delaying a recommended birth dose to investigate these hypotheses exposes newborns to avoidable risks. Former Guinea-Bissau Health Minister Magda Robalo and other critics have also raised concerns about conducting such research in a vulnerable population.

What Have Authorities Said?

The Bandim Health Project published an approval letter from Guinea-Bissau’s national ethics committee, dated July 14. A Danish research ethics committee also approved the study earlier this month.

However, transitional government Health Minister Quinhin Nantote disputed reports that the trial would proceed, telling The Guardian: “This is not even remotely true.”

WHO spokesperson Tarik Jašarević said a study denying newborns the vaccine would be “unethical” and expose them to “serious and potentially irreversible harm.” The WHO is advising Guinea-Bissau’s Ministry of Health on introducing the vaccine and assessing the study’s potential impact.

Why Is RFK Jr. Backing the Researchers?

Anthropologist Peter Aaby founded the Bandim Health Project in 1978. It is now co-led by his wife, epidemiologist Christine Stabell Benn.

Kennedy has called the pair “the deities of vaccine research” at an anti-vaccine conference and cited their research on the diphtheria-tetanus-pertussis (DTP) vaccine. A subsequent study by the researchers produced different results.

Kennedy also called Aaby a “very famous” researcher on Joe Rogan’s podcast in 2023 and cited his work when he halted US funding to Gavi, the Vaccine Alliance.

Stabell Benn served on the hepatitis B working group of the US Advisory Committee on Immunization Practices (ACIP) and presented evidence before the committee voted to end the universal hepatitis B birth-dose recommendation. A federal judge subsequently stayed the decision.